Zoladex in advanced breast cancer.
In the treatment of 53 premenopausal patients with advanced breast cancer, the LHRH analogue, Zoladex (goserelin), produced a response rate similar to that of surgical oophorectomy. Endocrinologically, Zoladex caused castrate levels of serum oestradiol and progesterone except in a small number of patients, where intermittent, suppressed peaks of oestradiol persisted. Treatment of 34 premenopausal patients with Zoladex combined with the anti-oestrogen tamoxifen (Nolvadex) produced significantly lower levels of serum oestradiol; all patients had castrate serum oestradiol levels. It is suggested that a prospective randomised study is necessary to determine any clinical advantage from such a combination.
Robertson
J F
JF
City Hospital, Nottingham, UK.
Nicholson
R I
RI
Walker
K J
KJ
Blamey
R W
RW
D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D017273:Goserelin; D006801:Humans; D010053:Ovary / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D013629:Tamoxifen; D017273:Goserelin; D002064:Buserelin